Last reviewed · How we verify

NCT04468386

Specimen Collection Study Protocol

Completed Last updated 24 November 2021
What this trial tests

trial in Focus in on Collecting Paired Specimens for Matrix Equivalency in 47 participants. Completed in 30 May 2021.

Timeline
7 July 2020
Primary endpoint
30 May 2021
30 May 2021

Quick facts

Lead sponsorBiomerica
StatusCompleted
Study typeOBSERVATIONAL
Enrollment47
Start date7 July 2020
Primary completion30 May 2021
Estimated completion30 May 2021
Sites1 location across United States

Conditions studied

Sponsor

Biomerica

Who can join

21 and older, any sex, with Focus in on Collecting Paired Specimens for Matrix Equivalency. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The specimens collected will be used to evaluate matrix equivalency in an immunoassay in development for the detection of IgG or IgA or IgM antibodies to SARS - CoV2 in human serum. These reagents are for in vitro diagnostic use only.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Biomerica trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04468386.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing